Figure 2From: Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell lineAlteration in protein expression in PC-3 cells treated with SB715992 and analyzed by Western Blot analysis. PC-3 cells were treated with 10 nM of SB715992 (A. p27/β-actin; B. p15/β-actin; C. IL-11/β-actin; D. EGFR/β-actin;).Back to article page